Inhibiting protein-protein interactions using designed molecules

Current Opinion in Structural Biology

Volumn 15, Issue 1 SPEC. ISS., 2005, Pages 31-34

  Zhao, Lei ^a   Chmielewski, Jean ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAZOLE; PEPTIDE DERIVATIVE; PROTEIN; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN P53; SCAFFOLD PROTEIN; TEREPHTHALIC ACID; TUMOR SUPPRESSOR PROTEIN;

CANCER THERAPY; CROSS LINKING; MEDICAL RESEARCH; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 13844275835     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sbi.2005.01.005     Document Type: Review

References (34)

1. M. Pellegrini, D. Haynor, and J.M. Johnson Protein interaction networks Expert Rev Proteomics 1 2004 239 249
2. J.D. Jordan, E.M. Landau, and R. Iyengar Signaling networks: the origins of cellular multitasking Cell 103 2000 193 200
3. D.R. Hipfner, and S.M. Cohen Connecting proliferation and apoptosis in development and disease Nat Rev Mol Cell Biol 5 2004 805 815
4. P.L. Toogood Inhibition of protein-protein association by small molecules: approaches and progress J Med Chem 45 2002 1543 1558
5. T. Berg Modulation of protein-protein interactions with small organic molecules Angew Chem Int Ed Engl 42 2003 2462 2481
6. T.R. Gadek, and J.B. Nicholas Small molecule antagonists of proteins Biochem Pharmacol 65 2003 1 8
7. M.R. Arkin, and J.A. Wells Small-molecule inhibitors of protein-protein interactions: progressing towards the dream Nat Rev Drug Discov 3 2004 301 317
8. L. Pagliaro, J. Felding, K. Audouze, S.J. Nielsen, R.B. Terry, C. Krog-Jensen, and S. Butcher Emerging classes of protein-protein interaction inhibitors and new tools for their development Curr Opin Chem Biol 8 2004 442 449
9. P. Li, and P.P. Roller Cyclization strategies in peptide derived drug design Curr Top Med Chem 2 2002 325 341
10. F. Sarabia, S. Chammaa, A.S. Ruiz, L.M. Ortiz, and F.J.L. Herrera Chemistry and biology of cyclic peptides of medicinal and biological interest Curr Med Chem 11 2004 1309 1332
11. R.J. Klasa, A.M. Gillum, R.E. Klem, and S.R. Frankel Oblimersen bcl-2 antisense: facilitating apoptosis in anticancer treatment Antisense Nucleic Acid Drug Dev 12 2002 193 213
12. Y. Gutierrez-Puente, P. Zapata-Benavides, A.M. Tari, and G. Lopez-Berestein Bcl-2-related antisense therapy Semin Oncol 29 2002 71 76
13. L-BID interaction in isolation and within cells.
14. A.M. Leduc, J.O. Trent, J.L. Wittliff, K.S. Bramlett, S.L. Briggs, N.Y. Chirgadze, Y. Wang, T.P. Burris, and A.F. Spatola Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions Proc Natl Acad Sci USA 100 2003 11273 11278 Lactam and disulfide cross-linked peptides have potent activity against the estrogen receptor-coactivator interaction.
15. T. Li, D. Saro, and M.R. Spaller Thermodynamic profiling of conformationally constrained cyclic ligands for the PDZ domain Bioorg Med Chem Lett 14 2004 1385 1388 A lactam-constrained peptide corresponding to the C-terminal sequence of the CRIPT protein is described that binds to the PDZ3 domain of the protein PSD-95.
16. M.E. Anderson, T. Yakovleva, Y.B. Hu, and T.J. Siahaan Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides Bioorg Med Chem Lett 14 2004 1399 1402
17. M.D. Shultz, Y.W. Ham, S.G. Lee, D.A. Davis, C. Brown, and J. Chmielewski Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach J Am Chem Soc 126 2004 9886 9887 A library of agents is described that target the dimerization interface of HIV-1 protease. Cross-reactivity with drug-resistant forms of HIV protease is demonstrated.
18. Y.S. Hwang, and J. Chmielewski A unidirectional crosslinking strategy for HIV-1 protease dimerization inhibitors Bioorg Med Chem Lett 14 2004 4297 4300 Potent inhibitors of HIV-1 protease dimerization are described, together with a novel strategy for cross-linking interfacial peptides.
19. Hwang YS, Chmielewski J: Development of low molecular weight HIV-1 protease dimerization inhibitors. J Med Chem 2005, in press.
20. I. Massova, and P.A. Kollman Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding free energies J Am Chem Soc 121 1999 8133 8143
21. O. Schon, A. Friedler, M. Bycroft, S.M.V. Freund, and A.R. Fersht Molecular mechanism of the interaction between MDM2 and p53 J Mol Biol 323 2002 491 501
22. J.A. Kritzer, J.D. Lear, M.E. Hodsdon, and A. Schepartz Helical beta-peptide inhibitors of the p53-hDM2 interaction J Am Chem Soc 126 2004 9468 9469 A 14-helix β-peptide helix is used as a scaffold to display the relevant functionality of the interfacial p53 helix. Inhibition of the p53-HDM2 interaction is described.
23. R. Fasan, Dias RLA, K. Moehle, O. Zerbe, J.W. Vrijbloed, D. Obrecht, and J.A. Robinson Using a beta-hairpin to mimic an alpha-helix: cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction Angew Chem Int Ed Engl 43 2004 2109 2112 A β-hairpin structure is used as a scaffold to display the relevant functionality of the interfacial p53 helix. Inhibition of the p53-HDM2 interaction is described.
24. O. Kutzki, H.S. Park, J.T. Ernst, B.P. Orner, H. Yin, and A.D. Hamilton Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry J Am Chem Soc 124 2002 11838 11839
25. L interaction is described.
26. S.E. VanCompernolle, A.V. Wiznycia, J.R. Rush, M. Dhanasekaran, P.W. Baures, and S.C. Todd Small molecule inhibition of hepatitis C virus E2 binding to CD81 Virology 314 2003 371 380 A novel bis-imidazole scaffold was used to generate a series of compounds that mimic (in a similar orientation and spatial arrangement) helix D of CD81. The inhibitors are found to bind reversibly to hepatitis C virus E2.
27. L.D. Jennings, K.W. Foreman, T.S. Rush, D.H.H. Tsao, L. Mosyak, Y.H. Li, M.N. Sukhdeo, W.D. Ding, E.G. Dushin, and C.H. Kenny Design and synthesis of indolo[2,3-alpha]quinolizin-7-one inhibitors of the ZipA-FtsZ interaction Bioorg Med Chem Lett 14 2004 1427 1431
28. L.D. Jennings, K.W. Foreman, T.S. Rush, D.H.H. Tsao, L. Mosyak, S.L. Kincaid, M.N. Sukhdeo, A.G. Sutherland, W.D. Ding, and C.H. Kenny Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction Bioorg Med Chem 12 2004 5115 5131
29. T. Ji, M. Lee, S.C. Pruitt, and D.G. Hangauer Privileged scaffolds for blocking protein-protein interactions: 1,4-disubstituted naphthalene antagonists of transcription factor complex HOX-PBX/DNA Bioorg Med Chem Lett 14 2004 3875 3879
30. C. Oneyama, T. Agatsuma, Y. Kanda, H. Nakano, S.V. Sharma, S. Nakano, F. Narazaki, and K. Tatsuta Synthetic inhibitors of proline-rich ligand-mediated protein-protein interaction: potent analogs of UCS15A Chem Biol 10 2003 443 451 A less toxic, smaller synthetic molecule was discovered to inhibit proline-rich ligand-mediated interaction between the Fyn SH3 domain and Sam68.
31. N. Fujii, J.J. Haresco, Novak KAP, D. Stokoe, I.D. Kuntz, and R.K. Guy A selective irreversible inhibitor targeting a PDZ protein interaction domain J Am Chem Soc 125 2003 12074 12075 Structure-based design was used to devise agents that mimic CRIPT, a ligand of the PDZ3 domain of the protein PSD-95. A designed compound was found that blocks ligand binding to the MAGI3 PDZ2 domain irreversibly.
32. C. Tan, L.H. Wei, F.P. Ottensmeyer, I. Goldfine, B.A. Maddux, C.C. Yip, R.A. Batey, and L.P. Kotra Structure-based de novo design of ligands using a three-dimensional model of the insulin receptor Bioorg Med Chem Lett 14 2004 1407 1410
33. C. Boussard, T. Klimkait, N. Mahmood, M. Pritchard, and I.H. Gilbert Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions Bioorg Med Chem Lett 14 2004 2673 2676
34. A.L. Rodriguez, A. Tamrazi, M.L. Collins, and J.A. Katzenellenbogen Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor a coactivator binding J Med Chem 47 2004 600 611